{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:36:56Z","timestamp":1761129416533},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,4,20]]},"DOI":"10.4103\/0366-6999.204107","type":"journal-article","created":{"date-parts":[[2017,4,10]],"date-time":"2017-04-10T10:09:59Z","timestamp":1491818999000},"page":"914-919","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and Safety of Tenofovir Disoproxil Treatment for Chronic Hepatitis B Patients with Genotypic Resistance to Other Nucleoside Analogues"],"prefix":"10.1097","volume":"130","author":[{"given":"Jing","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue-Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang-Shan","family":"Lian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Fang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Le","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Rong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-6-20210129","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2012 update","volume":"6","author":"Liaw","year":"2012","journal-title":"Hepatol Int"},{"key":"R5-6-20210129","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/hep.24078","article-title":"No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus","volume":"53","author":"Snow-Lampart","year":"2011","journal-title":"Hepatology"},{"key":"R6-6-20210129","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"R7-6-20210129","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jhep.2013.06.007","article-title":"Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment","volume":"59","author":"Seto","year":"2013","journal-title":"J Hepatol"},{"key":"R8-6-20210129","doi-asserted-by":"crossref","first-page":"e2013035","DOI":"10.4084\/mjhid.2013.035","article-title":"Tenofovir as rescue therapy following clinical failure to lamivudine in severe acute hepatitis B","volume":"5","author":"Gerada","year":"2013","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"R9-6-20210129","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S1542-3565(04)00017-5","article-title":"Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B","volume":"2","author":"Kuo","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R10-6-20210129","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijid.2014.09.004","article-title":"Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-na\u00efve patients with chronic hepatitis B: A multicenter real-life study","volume":"28","author":"Batirel","year":"2014","journal-title":"Int J Infect Dis"},{"key":"R11-6-20210129","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jhep.2013.11.024","article-title":"Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients","volume":"60","author":"Berg","year":"2014","journal-title":"J Hepatol"},{"key":"R12-6-20210129","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1136\/gutjnl-2014-308353","article-title":"Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: Results of a randomised trial","volume":"65","author":"Lim","year":"2016","journal-title":"Gut"},{"key":"R13-6-20210129","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3904\/kjim.2015.30.1.32","article-title":"Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients","volume":"30","author":"Kim","year":"2015","journal-title":"Korean J Intern Med"},{"key":"R14-6-20210129","doi-asserted-by":"crossref","first-page":"e106324","DOI":"10.1371\/journal.pone.0106324","article-title":"Differential binding of tenofovir and adefovir to reverse transcriptase of hepatitis B virus","volume":"9","author":"van Hemert","year":"2014","journal-title":"PLoS One"},{"key":"R15-6-20210129","first-page":"697","article-title":"Tenofovir rescue therapy for chronic hepatitis B patients after suboptimal response to treatment with lamivudine plus adefovir dipivoxil (in Chinese)","volume":"53","author":"Ge","year":"2014","journal-title":"Chin J Intern Med"},{"key":"R16-6-20210129","first-page":"266","article-title":"Efficacy of 48-week tenofovir disoproxil fumarate therapy in patients who were unresponsive to nucleoside-analogue treatments (in Chinese)","volume":"22","author":"Huang","year":"2014","journal-title":"Chin J Hepatol"},{"key":"R17-6-20210129","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3851\/IMP1914","article-title":"Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside\/nucleotide analogues","volume":"17","author":"Lim","year":"2012","journal-title":"Antivir Ther"},{"key":"R18-6-20210129","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/gut.2010.223206","article-title":"Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B","volume":"60","author":"Patterson","year":"2011","journal-title":"Gut"},{"key":"R19-6-20210129","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.23246","article-title":"Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside\/nucleotide analogues","volume":"51","author":"van B\u00f6mmel","year":"2010","journal-title":"Hepatology"},{"key":"R20-6-20210129","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N Engl J Med"},{"key":"R21-6-20210129","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/hep.26686","article-title":"No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B","volume":"59","author":"Kitrinos","year":"2014","journal-title":"Hepatology"},{"key":"R22-6-20210129","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s10620-014-3486-7","article-title":"Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection","volume":"60","author":"Buti","year":"2015","journal-title":"Dig Dis Sci"},{"key":"R23-6-20210129","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/hep.26277","article-title":"Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load","volume":"58","author":"Gordon","year":"2013","journal-title":"Hepatology"},{"key":"R24-6-20210129","first-page":"1585","article-title":"Hepatitis B virus in tenofovir-naive Chinese patients with chronic hepatitis B contains no mutation of rtA194T conferring a reduced tenofovir susceptibility","volume":"122","author":"Liu","year":"2009","journal-title":"Chin Med J"},{"key":"R25-6-20210129","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/135965350701200309","article-title":"In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents","volume":"12","author":"Qi","year":"2007","journal-title":"Antivir Ther"},{"key":"R26-6-20210129","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1473-3099(11)70314-0","article-title":"Selection of chronic hepatitis B therapy with high barrier to resistance","volume":"12","author":"Gish","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"R27-6-20210129","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMra065142","article-title":"Viral hepatitis in HIV infection","volume":"356","author":"Koziel","year":"2007","journal-title":"N Engl J Med"},{"key":"R28-6-20210129","doi-asserted-by":"crossref","first-page":"304","DOI":"10.4103\/0366-6999.174509","article-title":"Efficacy and safety of tenofovir and lamivudine in combination with efavirenz in patients co-infected with human immunodeficiency virus and hepatitis B virus in China","volume":"129","author":"Wu","year":"2016","journal-title":"Chin Med J"},{"key":"R29-6-20210129","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2147\/DDDT.S65349","article-title":"Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir","volume":"8","author":"Suzuki","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"R30-6-20210129","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jcv.2014.09.016","article-title":"Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal","volume":"61","author":"Vigan\u00f2","year":"2014","journal-title":"J Clin Virol"},{"key":"R31-6-20210129","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3851\/IMP2649","article-title":"Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B monoinfection","volume":"18","author":"Gracey","year":"2013","journal-title":"Antivir Ther"},{"key":"R32-6-20210129","first-page":"342","article-title":"Tenofovir-associated Fanconi syndrome in a patient with chronic hepatitis B","volume":"23","author":"Samarkos","year":"2014","journal-title":"J Gastrointestin Liver Dis"},{"key":"R33-6-20210129","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1002\/hep.27730","article-title":"Tenofovir-associated Fanconi syndrome and nephrotic syndrome in a patient with chronic hepatitis B monoinfection","volume":"62","author":"Hwang","year":"2015","journal-title":"Hepatology"},{"key":"R34-6-20210129","first-page":"313A","article-title":"Long Term Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Infection is Safe and Well Tolerated and Associated with Durable Virologic Response with no Detectable Resistance: 8 Year Results from Two Phase 3 Trials","volume":"60","author":"Marcellin","year":"2014","journal-title":"Hepatology"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.4103\/0366-6999.204107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T10:17:33Z","timestamp":1658917053000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00029330-201704200-00006"}},"subtitle":["A Prospective Study"],"short-title":[],"issued":{"date-parts":[[2017,4,20]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.4103\/0366-6999.204107","relation":{},"ISSN":["0366-6999"],"issn-type":[{"value":"0366-6999","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4,20]]}}}